Legal status · Australia
Is VK2735 legal in Australia?
No. VK2735 is not approved for any medical use in Australia; its classification is "Investigational, not registered". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. Human evidence to date: Moderate.
VK2735 in Australia at a glance
| Classification | Investigational, not registered |
|---|---|
| TGA approval status | Not approved by TGA; investigational |
| Evidence level | Moderate (research strength: Moderate) |
| Reviewed | Sep 2026 |
Classification and note come from the VK2735 profile, checked against Therapeutic Goods Administration (TGA) listings at the reviewed date.
What this means
- 01
VK2735 is being studied in registered clinical trials but has not received TGA marketing approval in Australia.
- 02
Lawful human access is limited to trial participation or a formal early-access scheme where one exists; there is no pharmacy product to prescribe.
- 03
Vials sold online "for research use only" are not trial material, and that label does not make human use lawful.
What VK2735 is
Viking Therapeutics' dual GLP-1 and GIP agonist in Phase 3 as an injection, with an oral version showing rapid early weight loss.
VK2735 is Viking Therapeutics' dual GLP-1 and GIP receptor agonist, in the same mechanistic class as tirzepatide. 2% at 13 weeks, among the fastest early responses of any oral agent.
Mechanism: Agonizes both the GLP-1 and GIP receptors to enhance insulin secretion, reduce appetite, and slow gastric emptying.
Regulatory history: Investigational (Phase 3 VANQUISH-1 and VANQUISH-2 fully enrolled; oral form completed Phase 2)
How TGA treats this kind of product
Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.
The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for VK2735 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
VK2735 in other countries
Frequently asked questions
Is VK2735 legal in Australia?
No. VK2735 is not approved for any medical use in Australia; its classification is "Investigational, not registered". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. Human evidence to date: Moderate.
Can I buy VK2735 in Australia?
No approved product exists to buy. In Australia VK2735 is classified as "Investigational, not registered", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors.
Is VK2735 TGA approved?
No. In Australia VK2735 is classified as "Investigational, not registered", which is not a TGA marketing approval. For comparison, the US FDA status is: Investigational (Phase 3 VANQUISH-1 and VANQUISH-2 fully enrolled; oral form completed Phase 2). Evidence level: Moderate.
Related compounds in Australia
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for VK2735 live on its compound profile.
VK2735 profileThis page is general information about the regulatory status of VK2735 in Australia, current as of Sep 2026. It is not legal advice, and classifications change; check Therapeutic Goods Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.